...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis
【24h】

Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis

机译:二氢叶酸合酶中的结合口袋改变赋予结核分枝杆菌临床分离株对对氨基水杨酸抗性

获取原文
获取原文并翻译 | 示例

摘要

The mechanistic basis for the resistance of Mycobacterium tuberculosis to para-aminosalicylic acid (PAS), an important agent in the treatment of multidrug-resistant tuberculosis, has yet to be fully defined. As a substrate analog of the folate precursor paraaminobenzoic acid, PAS is ultimately bioactivated to hydroxy dihydrofolate, which inhibits dihydrofolate reductase and disrupts the operation of folate-dependent metabolic pathways. As a result, the mutation of dihydrofolate synthase, an enzyme needed for the bioactivation of PAS, causes PAS resistance in M. tuberculosis strain H37Rv. Here, we demonstrate that various missense mutations within the coding sequence of the dihydropteroate (H2Pte) binding pocket of dihydrofolate synthase (FolC) confer PAS resistance in laboratory isolates of M. tuberculosis and Mycobacterium bovis. From a panel of 85 multidrug-resistant M. tuberculosis clinical isolates, 5 were found to harbor mutations in the folC gene within the H2Pte binding pocket, resulting in PAS resistance. While these alterations in the H2Pte binding pocket resulted in reduced dihydrofolate synthase activity, they also abolished the bioactivation of hydroxy dihydropteroate to hydroxy dihydrofolate. Consistent with this model for abolished bioactivation, the introduction of a wild-type copy of folC fully restored PAS susceptibility in folC mutant strains. Confirmation of this novel PAS resistance mechanism will be beneficial for the development of molecular method-based diagnostics for M. tuberculosis clinical isolates and for further defining the mode of action of this important tuberculosis drug.
机译:结核分枝杆菌对对氨基水杨酸(PAS)的抗药性机制基础尚不清楚,抗药性是治疗耐多药结核病的重要药物。作为叶酸前体对氨基苯甲酸的底物类似物,PAS最终被生物激活为羟基二氢叶酸,从而抑制了二氢叶酸还原酶并破坏了叶酸依赖性代谢途径的运作。结果,二氢叶酸合酶(PAS的生物激活所必需的一种酶)的突变导致结核分枝杆菌菌株H37Rv对PAS产生抗性。在这里,我们证明了在结核分枝杆菌和牛分枝杆菌的实验室分离物中,二氢叶酸合酶(FolC)的二氢蝶呤(H2Pte)结合口袋的编码序列内的各种错义突变赋予了PAS抗性。从一组85个耐多药结核分枝杆菌临床分离株中,发现5个在H2Pte结合口袋内的folC基因中具有突变,从而导致PAS耐药。虽然H2Pte结合口袋中的这些改变导致二氢叶酸合酶活性降低,但它们也取消了羟基二氢蝶呤对羟基二氢叶酸的生物活化作用。与取消生物激活的该模型一致,野生型拷贝的folC的引入完全恢复了folC突变菌株中PAS的敏感性。这种新颖的PAS抗药性机制的确认,将有助于开发基于分子方法的结核分枝杆菌临床分离株诊断方法,并进一步确定这种重要的结核病药物的作用方式。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号